Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India

Abstract

Background & objectives:Drug-induced diseases (DIDs) are well known but least studied. Data on DIDs from India are not available. Hence, this retrospective cross-sectional study was undertaken using suspected adverse drug reaction (ADR) data collected form Pharmacovigilance Programme of India (PvPI) to evaluate profile of DIDs over two years, in a tertiary care teaching hospital from north India.Methods:The suspected ADRs in the form of DID were evaluated for drug and disease related variables and were classified in terms of causality.Results:DID rate was 38.80 per cent. Mean duration of developing DIDs was 26.05 ± 9.6 days; 25.16 per cent had more than one co-morbid condition. Geriatric population (53.99%) accounted for maximum DIDs followed by adult (37.79%) and paediatric (8.21%). Maximum events were probable (93.98%) followed by possible (6.04%). All DIDs required intervention. Gastritis (7.43%), diarrhoea (5.92%), anaemia (4.79%), hypotension (2.77%), hepatic dysfunction (2.69%), hypertension (1.51%), myalgia (1.05%), and renal dysfunction (1.01%) were some of the DIDs. Anti tubercular treatment (ATT), anti retroviral treatment (ART), ceftriaxone injection, steroids, non-steroidal anti-inflammatory drugs, antimicrobials and anticancer drugs were found as commonly offending drugs.Interpretation & conclusions:Our findings show that DIDs are a significant health problem in our country, which need more attention.

Drug induced diseases (DID): Need for more awareness & research

“…Likewise a prospective study from Portugal reported that 22.9 per cent of patients admitted in the department of internal medicine developed iatrogenic disease 5 . In the present study by Tandon and colleagues 1 , the reported incidence of DID is 38.8 per cent. However, contrary to previous studies, the present study was retrospective and the data were obtained from the ADRs reported to Adverse Drug Reaction Monitoring Center, functioning under PvPI.…”

“…The true incidence or prevalence of DID in our country is not known. The results of the study by Tandon et al 1 in this issue provide information on DID in Indian setting. Although the study has a few limitations and overlap between adverse drug reactions (ADR) and DID, yet it flags an important issue which needs attention.…”

“…Further, future studies should also focus on elderly who are prone to have chronic illness, consulting multiple physicians and receive polypharmacy. Most of the published reports on DID are from tertiary care hospitals including the present one 1 . However, the epidemiology of ADR (including DID) occurring in primary care and in general practice remains uncertain.…”

Clinical Pharmacology in India-A Systematic Review of Research in the Past 5 Years

“…However, these were not considered further due to lack of any systematic investigation into causes or frequency of occurrence. Similarly, several studies and systematic reviews evaluated the occurrence of ADRs among people receiving pharmacotherapy in hospitals and/or in community settings (Geer et al, 2016;Tandon et al, 2015;Hiware et al, 2013;Patel and Patel, 2016;Patel et al, 2014;Patel et al, 2013). Although antimicrobials were often found to be a major contributor to adverse reactions experienced by patients, these studies were not included since their primary focus was not on antimicrobial safety.…”

Multiple Regression Analysis and Frequent Itemset Mining of Electronic Medical Records: A Visual Analytics Approach Using VISA_M3R3

“…The amount of prescription data available to clinical researchers, pharmaceutical scientists, and clinician-scientists continues to grow, creating an analyzable resource for generating insights that can help improve the healthcare system [4,5]. Healthcare providers use modern EMR-based systems to identify adverse drug events [6,7], study medication-medication interactions [8], investigate medication effects on particular medical conditions [9,10], and ultimately prevent medication errors [11][12][13].…”